Kezar Life Sciences (KZR) Common Equity (2021 - 2025)
Historic Common Equity for Kezar Life Sciences (KZR) over the last 5 years, with Q3 2025 value amounting to $83.0 million.
- Kezar Life Sciences' Common Equity fell 3810.02% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.0 million, marking a year-over-year decrease of 3810.02%. This contributed to the annual value of $116.9 million for FY2024, which is 3766.81% down from last year.
- Per Kezar Life Sciences' latest filing, its Common Equity stood at $83.0 million for Q3 2025, which was down 3810.02% from $91.8 million recorded in Q2 2025.
- In the past 5 years, Kezar Life Sciences' Common Equity registered a high of $297.4 million during Q2 2022, and its lowest value of $83.0 million during Q3 2025.
- Moreover, its 5-year median value for Common Equity was $169.1 million (2024), whereas its average is $179.3 million.
- In the last 5 years, Kezar Life Sciences' Common Equity skyrocketed by 13701.51% in 2022 and then tumbled by 3908.75% in 2025.
- Quarter analysis of 5 years shows Kezar Life Sciences' Common Equity stood at $196.9 million in 2021, then soared by 37.08% to $269.9 million in 2022, then crashed by 30.5% to $187.6 million in 2023, then crashed by 37.67% to $116.9 million in 2024, then decreased by 29.03% to $83.0 million in 2025.
- Its Common Equity stands at $83.0 million for Q3 2025, versus $91.8 million for Q2 2025 and $103.1 million for Q1 2025.